Firefly Neuroscience Advances AI BNA™ Technology in Drug Development with Takeda and Novartis
Saturday, September 21, 2024
Firefly Neuroscience has advanced its Brain Network Analytics (BNA™) technology following successful research collaborations with Takeda Pharmaceutical Company Limited and Novartis.
The integration of Firefly’s BNA™ technology into central nervous system (CNS) drug development offers biotech and pharmaceutical companies tools to improve patient and dose selection.
These partnerships highlight the potential of Firefly’s AI-based technology in providing objective measurements in neuroscience drug development.
This has the potential to reduce costs and accelerate drug development by providing more precise assessments of drug effects on brain activity.
The technology also aids in identifying patients who are more likely to respond to treatments, leading to better clinical outcomes.
Firefly aims to expand its partnerships within the neuroscience pharmaceutical sector, building on its collaborations with leading companies like Takeda and Novartis.
The company believes that electrophysiology-based biomarkers, such as BNA™, represent a valuable asset in streamlining drug development and addressing the challenges posed by the high cost of new medications.
Source: globenewswire.com
